文献速递前列腺癌

转移性前列腺癌患者放射学进展模式的异质性及其与结局的关联

Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-12-26

该研究基于LATITUDE和COU-AA-302两项三期随机研究的个体患者数据进行回顾性二次分析,评估转移性激素敏感性前列腺癌(mHSPC)和转移性去势抵抗性前列腺癌(mCRPC)患者中不同放射学进展模式的比例及与影像学无进展生存期(rPFS)和进展后生存期(PPS)的关联。结果显示多类别放射学进展患者约占25%,其rPFS与单类别进展者相当,但PPS显著更短。

要点

  • mHSPC患者中25.2%(123/489)出现多类别放射学进展,mCRPC患者中27.0%(144/534)出现多类别进展。
  • mCRPC患者中骨进展的rPFS最短;mHSPC患者中靶病灶增大的rPFS最短,其次为骨进展。
  • 多类别进展患者PPS显著短于单类别进展者(mHSPC:6.9 vs 21.5个月,p<0.0001;mCRPC:15.7 vs 23.6个月,p<0.0001)。

核心结论

  • 多类别放射学进展患者占mHSPC或mCRPC患者的约25%,其rPFS与单类别进展者相当,但PPS显著更短。
  • 作者认为未来临床试验和临床实践中应将放射学进展模式视为预后的关键决定因素,并作为二线治疗临床试验的分层或纳入标准。

研究设计与样本

  • 基于LATITUDE(三期随机mHSPC研究)和COU-AA-302(三期随机mCRPC研究)个体患者数据的回顾性二次分析(post hoc)。
  • 纳入具有完整影像学随访数据且出现放射学进展的患者:mHSPC 489例,mCRPC 534例。

主要发现

  • mHSPC患者中366例为单类别进展,123例(25.2%)为多类别放射学进展。
  • mCRPC患者中390例为单类别进展,144例(27.0%)为多类别进展。
  • mCRPC患者中骨进展的rPFS最短;mHSPC患者中靶病灶增大的rPFS最短,其次为骨进展。
  • 单类别进展患者rPFS与多类别进展者相当,但PPS显著更长(mHSPC队列:21.5 vs 6.9个月,p<0.0001;mCRPC队列:23.6 vs 15.7个月,p<0.0001)。

临床怎么用

  • 作者认为未来临床试验和临床实践中应将放射学进展模式视为预后的关键决定因素。
  • 作者认为放射学进展模式可作为二线治疗临床试验的分层或纳入标准。

局限性

  • 本研究为假设生成性研究(hypothesis-generating nature)。
  • 研究所观察到的现象需通过未来前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With an increasing number of clinical trials using radiographic progression-free survival (rPFS) instead of overall survival as the primary study endpoint, the heterogeneity of different radiological progression patterns in rPFS and postprogression survival (PPS) remains unclear. OBJECTIVE: Herein, we investigate the proportion of various radiological progression patterns in patients with metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC), and further explore the differences in rPFS and PPS between patients exhibiting single- or multicategory progression patterns. DESIGN, SETTING, AND PARTICIPANTS: This post hoc, retrospective secondary analysis was based on individual patient data from LATITUDE (phase 3 randomized mHSPC study) and COU-AA-302 (phase 3 randomized mCRPC study). Patients with complete imaging follow-up data and radiological progression were included in the analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The rPFS and PPS in LATITUDE and COU-AA-302 were evaluated. The proportion of patients exhibiting each progression pattern was calculated, and a survival analysis was conducted using the Kaplan-Meier method. RESULTS AND LIMITATIONS: Of the 489 mHSPC patients studied, 366 experienced single-category progression, while the remaining 123 patients (25.2%) exhibited simultaneous occurrence of different progressive events (multicategory radiological progression). Of the 534 mCRPC patients studied, 390 experienced single-category progression, while the remaining 144 patients (27.0%) experienced multicategory progressive events. Among mCRPC patients, the rPFS of bone progression was the shortest. In contrast, among mHSPC patients, the rPFS of target lesion enlargement is the shortest, followed by bone progression. Notably, patients experiencing a single-category progression pattern displayed comparable rPFS to but significantly longer PPS than those experiencing multicategory progression patterns (PPS mHSPC cohort: 21.5 vs 6.9 mo, p < 0.0001; mCRPC cohort: 23.6 vs 15.7 mo, p < 0.0001). The study is limited by its hypothesis-generating nature. Therefore, the observed phenomena in our research necessitate validation through future prospective studies. CONCLUSIONS: Patients who experience multicategory radiological progression represent a significant proportion, accounting for approximately 25% of all men with mHSPC or mCRPC. Patients with multicategory radiological progression patterns had similar rPFS to but significantly shorter PPS than those experiencing single-category progression patterns. In future clinical trials and clinical practice, radiological progression patterns should be recognized as a crucial determinant of prognosis, while also serving as the stratification or inclusion criteria for second-line treatment clinical trials. PATIENT SUMMARY: In this study, we observed that among men with metastatic prostate cancer, those who experienced two or more radiological events during a single visit had a worse prognosis than those who experienced isolated radiological events.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ni X, Wu J, Pan J, et al. Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer. Eur Urol Oncol. 2023. PMID: 38151441. doi:10.1016/j.euo.2023.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。